A phase 2 trial of trastuzumab deruxtecan (T-DXd, DS-8201) in patients with HER2-positive, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma-MedSci.cn

A phase 2 trial of trastuzumab deruxtecan (T-DXd, DS-8201) in patients with HER2-positive, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma

Fuchs, C; Shahidi, J; Mathew, L; Qin, A; Van Cutsem, E

ANNALS OF ONCOLOGY, 2020; 31 (): S150

科室
- - 订阅+
  - 更多科室
工具
服务